李君,冯高科,郑晓新,卢钊,秦超师,陈燕,肖建民,夏金喜,翟健坤,吴天根,蒋学俊,李晓艳

• 1:武汉大学人民医院心内科
• 2:南方医科大学实验动物中心
• 3:东莞市太平人民医院
• 4:东莞天天向上医疗科技有限公司

摘要(Abstract)：

目的评价聚左旋乳酸/无定形磷酸钙(PLLA/ACP)新型生物全降解药物支架置入猪冠状动脉6个月内支架弹性回缩及有效性。方法将16枚新型生物支架随机置入小型猪冠状动脉内,行冠状动脉造影检查(术后即刻、随访终点)和血管内超声(IVUS)检查(术后即刻、1个月、6个月),并且,在术后1个月和6个月分别处死12、4只动物,取支架置入部位血管固定行苏木素-伊红(HE)染色,观察内膜增生情况和支架贴壁情况。结果各小型猪随访终点造影复查可见支架置入段血管血流通畅,无狭窄及血栓形成等现象。IVUS检查提示,平均支架面积和平均支架直径在置入术后1个月和术后6个月时分别与术后即刻比较,差异均无统计学意义[平均支架面积:(6.08±1.30)mm2、(6.00±0.60)mm2比(5.97±0.53)mm2,P>0.05;平均支架直径:(2.76±0.30)mm、(2.76±0.14)mm比(2.75±0.12)mm,P>0.05],提示支架未发生显著弹性回缩;病理形态学分析提示,支架置入段血管轻度狭窄,未见支架贴壁不良。结论新型生物全降解支架置入小型猪冠状动脉6个月后,未发现显著支架弹性回缩,具有足够的支撑性能;内膜增生程度较轻,能够保证管腔通畅。

关键词(KeyWords)： 生物全降解药物洗脱支架;冠状动脉造影;连续血管内超声

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李君,冯高科,郑晓新,卢钊,秦超师,陈燕,肖建民,夏金喜,翟健坤,吴天根,蒋学俊,李晓艳

参考文献(References)：

• [1]van der Hoeven BL,Pires NM,Warda HM,et al.Drug-eluting stents:results,promises and problems.Int J Cardiol,2005,99:9-17.
• [2]Joner M,Finn AV,Farb A,et al.Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Cardiol,2006,48:193-202.
• [3]Nakazawa G,Finn AV,Joner M,et al.Delayed arterial healing and increased late stent thrombosis at culprit sites after drugeluting stent placement for acute myocardial infarction patients:an autopsy study.Circulation,2008,118:1138-1145.
• [4]Serruys PW,Ormiston JA,Onuma Y,et al.A bioabsorbable everolimus-eluting coronary stent system(ABSORB):2-year outcomes and results from multiple imaging methods.Lancet,2009,373:897-910.
• [5]Komowski R,Hong MK,Tio FO,et al.In-stent restenosis:contributions of inflammatory responses and arterial injury to neointmial hyperplasia.J Am Coll Cardiol,1998,31:224-230.
• [6]Zheng X,Wang Y,Lan Z,et al.Improved biocompatibility of poly(lactic-co-glycolic acid)orv and poly-L-lactic acid blended with nanoparticulate amorphous calcium phosphate in vascular stent applications.J Biomed Nanotechnol,2014,10:900-910.
• [7]贺素媛,李虎,任珊,等.新型生物全降解药物释放支架对小型实验猪冠状动脉内膜的影响.中国介入心脏病学杂志,2013:178-183.
• [8]Iqbal J,Gunn J,Serruys PW.Coronary stents:historical development,current status and future directions.Br Med Bull,2013,106:193-211.
• [9]Tamai H,Igaki K,Kyo E,et al.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.Circulation,2000,102:399-404.
• [10]Kim I,Kim HJ,Kim HM.Array of amorphous calcium phosphate particles improves cellular activity on a hydrophobic surface.J Biomed Mater Res B Appl Biomater,2010,93:113-121.
• [11]Kokubo T,Kim HM,Kawashita M.Novel bioactive materials with different mechanical properties.Biomaterials,2003,24:2161-2175.
• [12]Lan Z,Lyu Y,Xiao J,et al.Novel biodegradable drug-eluting stent composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles demonstrates improved structural and functional performance for coronary artery disease.J Biomed Nanotechnol,2014,10:1194-1204.
• [13]吴轶喆,葛雷,沈雳,等.连续血管内超声评价完全可降解聚-L-乳酸支架植入猪冠状动脉1个月支架弹性回缩.中国介入心脏病学杂志,2013:172-177.
• [14]Tan LP,Venkatraman SS,Joso JF,et al.Collapse pressures of bilayered biodegradable stents.J Biomed Mater Res B Appl Biomater,2006,79:102-107.